In particular, germline MMR LPVs/PVs were detected in 18 (38.3%) out of 47 CRC patients selected by means of revised Bethesda guidelines, 9 (27.3%) out of 33 subjects screened for Amsterdam criteria II, and 5 (25%) out of 20 patients recruited for negative IHC MMR testing. This evidence concerns the gene MRC1 and colorectal carcinoma.